Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: A meta-analysis of individual patient data

The Lancet Oncology

Volumn 15, Issue 3, 2014, Pages 333-342

  Palumbo, Antonio ^a   Bringhen, Sara ^a   Kumar, Shaji K ^d   Lupparelli, Giulia ^a   Usmani, Saad ^e   Waage, Anders ^f   Larocca, Alessandra ^a   Van Der Holt, Bronno ^g   Musto, Pellegrino ^h   Offidani, Massimo ^c   Petrucci, Maria T ⁱ   Evangelista, Andrea ^b   Zweegman, Sonja ^j   Nooka, Ajay K ^k   Spencer, Andrew ^l   Dimopoulos, Meletios A ^m   Hajek, Roman ⁿ   Cavo, Michele ^o   Richardson, Paul ^p   Lonial, Sagar ^k   Ciccone, Giovannino ^b   Boccadoro, Mario ^a   Anderson, Kenneth ^p   Barlogie, Bart ^e   Sonneveld, Pieter ^g   McCarthy, Philip L ^q   more..

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d Mayo Clinic   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h REFERRAL CANCER CENTER OF BASILICATA   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k EMORY UNIVERSITY   (United States)

^l MONASH UNIVERSITY   (Australia)

^m UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁿ UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^o UNIVERSITY OF BOLOGNA   (Italy)

^p DANA FARBER CANCER INSTITUTE   (United States)

^q ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CAUSE OF DEATH; DRUG EXPOSURE; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS; MULTIPLE MYELOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECOND CANCER; TREATMENT DURATION;

ANGIOGENESIS INHIBITORS; HUMANS; MELPHALAN; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; THALIDOMIDE;

EID: 84896711459     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70609-0     Document Type: Article

References (33)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
2. Pulte D, Gondos A, Brenner H Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist 2011, 16:1600-1603.
3. Palumbo A, Anderson K Multiple myeloma. N Engl J Med 2011, 364:1046-1060.
4. Yang J, Terebelo HR, Zonder JA Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited. Adv Hematol 2012, 2012:801495.
5. Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 2012, 119:2731-2737.
6. SEER cancer statistics review, 1975-2010 2013, National Cancer Institute, Bethesda, MD, based on November 2012 SEER data submission, posted to the SEER website, (accessed Nov 28, 2013). http://seer.cancer.gov/csr/1975_2010/, N. Howlader, A.M. Noone, M. Krapcho (Eds.).
7. Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011, 118:4086-4092.
8. Cuzick J, Erskine S, Edelman D, Galton DA A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. Br J Cancer 1987, 55:523-529.
9. Krishnan AY, Mei M, Sun CL, et al. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2013, 19:260-265.
10. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012, 366:1759-1769.
11. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366:1782-1791.
12. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366:1770-1781.
13. Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012, 119:2764-2767.
14. Gooley TA, Leisenring W, Crowley J, Storer BE Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
15. Zhou B, Fine J, Latouche A, Labopin M Competing risks regression for clustered data. Biostat Oxf Engl 2012, 13:371-383.
16. Zweegman S, Mellqvist UH, Montfort CV, Salomo M Randomized phase 3 trial in elderly NDMM comparing MPT followed by T maintenance versus MPR followed by R maintenance. Clin Lymphoma Myeloma Leuk 2013, 13(suppl 1):S40-S41. (abstr O-8).
17. Gay F, Hajek R, Di Raimondo F, Genuardi M Cyclophosphamide-lenalidomide-dexamethasone vs autologous transplant in newly diagnosed myeloma: a phase 3 trial. Clin Lymphoma Myeloma Leuk 2013, 13(suppl 1):S40. (abstr O-7).
18. Larocca A, Magarotto V, Offidani M, Pour L Lenalidomide-dexamethasone vs melphalan-prednisone-lenalidomide vs cyclophosphamide-prednisone-lenalidomide in NDMM. Clin Lymphoma Myeloma Leuk 2013, 13(suppl 1):S113. (abstr P-146).
19. Palumbo AP, Cavallo F, Hardan I, Lupo B, Omede P Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients <65 years: results of a randomized phase III study. Blood 2011, 118:3069. (abstr).
20. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11:29-37.
21. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010, 116:5838-5841.
22. Landgren O, Ma W, Kyle RA, Rajkumar SV, Korde N, Albitar M Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma. Leukemia 2012, 26:844-845.
23. Barlogie B, Tricot G, Haessler J, et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood 2008, 111:94-100.
24. Reddi DM, Lu CM, Fedoriw G, et al. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens. Am J Clin Pathol 2012, 138:855-866.
25. Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 1986, 105:360-367.
26. Howe R, Micallef IN, Inwards DJ, et al. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2003, 32:317-324.
27. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:2208-2214.
28. Larocca A, Oliva S, Offidani M, et al. Subcutaneous velcade plus prednisone (VP) or plus cyclophosfamide (VCP) or plus melphalan (VMP) in frail, elderly, newly diagnosed multiple myeloma patients: a phase II community-based study. Haematologica 2013, 98(suppl 1):477. (abstr S1154).
29. Niesvizky R, Flinn IW, Rifkin R, et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. Blood 2011, 118:478.
30. Thalidomide Celgene. Procedural steps taken and scientific information after the authorisation European Medicines Agency, (accessed July 1, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000823/WC500037055.pdf.
31. Thalidomide Celgene. Summary of product characteristics European Medicines Agency, (accessed July 1, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000823/WC500037050.pdf.
32. Chakraborty S, Hauke RJ, Bonthu N, Tarantolo SR Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma-a SEER based study. Anticancer Res 2012, 32:4507-4515.
33. Usmani SZ, Sexton R, Hoering A, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 2012, 120:1597-1600.